UBAC2

UBAC2 is a multi-pass transmembrane endoplasmic reticulum protein that serves as a selective ER-phagy (reticulophagy) receptor, coupling ER turnover to the control of inflammatory signaling (PMID:39284914, PMID:39580148). Its cytoplasmic domain carries a canonical LC3-interacting region (LIR) that binds the autophagosomal protein GABARAP, enabling targeted autophagic degradation of ER fragments (PMID:39284914, PMID:39580148). This receptor activity is switched on by phosphorylation: MARK2 phosphorylates UBAC2 at serine 223, driving UBAC2 dimerization, which strengthens GABARAP binding and advances ER-phagy (PMID:39284914, PMID:39580148). Through this pathway UBAC2-mediated ER-phagy limits ER stress (UPR) and restrains inflammation, with loss of function increasing UPR activation and aggravating acute ulcerative colitis in mice (PMID:39284914); consistent with an anti-inflammatory role, UBAC2 negatively regulates the Nur77/IKKβ/NF-κB axis (PMID:34074311). UBAC2 protein levels are set by ubiquitin-proteasome-mediated degradation, as proteasome inhibition with PS-341 stabilizes the protein (PMID:34074311), while its transcription is positively driven by CTCF acting at a promoter polymorphism (PMID:35020141). Genetic variants in UBAC2 that alter its transcript expression are associated with Behçet's disease (PMID:21918955, PMID:22455605).

1. 2011 Medium

   Established that UBAC2 is a disease-relevant locus whose expression is genetically tunable, raising the question of what UBAC2 does mechanistically.

   Evidence Haplotype conditional analysis and real-time PCR of a UBAC2 transcript variant in PBMCs stratified by rs7999348 genotype

   PMID:21918955 PMID:22455605

   Open questions at the time

   • Does not define UBAC2 protein function
   • Causal link between transcript variant level and disease mechanism unresolved
2. 2012 Medium

   Showed that a specific promoter polymorphism quantitatively controls UBAC2 transcription, pinpointing a cis-regulatory mechanism for the disease association.

   Evidence Luciferase reporter assay and real-time PCR of UBAC2 in PBMCs and skin stratified by rs3825427 genotype

   PMID:22455605

   Open questions at the time

   • Trans-acting factor binding the promoter not identified
   • Does not connect transcript level to a cellular function
3. 2021 Medium

   Defined the first functional handles on UBAC2 protein — that it is a 4-transmembrane, ubiquitin-binding protein turned over by the proteasome and that it suppresses an inflammatory signaling axis.

   Evidence TM4/UBAC2 knockout mouse, PS-341 proteasome inhibition in vitro and in db/db mice, and Nur77/IKKβ/NF-κB pathway readouts

   PMID:34074311

   Open questions at the time

   • E3 ligase and degron driving proteasomal turnover not identified
   • Molecular mechanism linking UBAC2 to NF-κB suppression unresolved
   • Single lab
4. 2022 Medium

   Identified the trans-acting regulator of UBAC2 transcription, showing CTCF binds the promoter polymorphism as an enhancer to activate expression.

   Evidence Luciferase reporter with CTCF overexpression and rs3825427 mutation, plus siRNA knockdown of CTCF with UBAC2 mRNA measurement

   PMID:35020141

   Open questions at the time

   • Whether CTCF regulation operates in disease-relevant cell types in vivo unaddressed
   • Single lab, focused on one SNP
5. 2024 High

   Resolved the core molecular function of UBAC2 as a LIR-containing ER-phagy receptor for GABARAP, and showed MARK2 phosphorylation at S223 acts as the activating switch via dimerization, linking ER turnover to restraint of ER-stress-driven inflammation.

   Evidence LIR motif identification with GABARAP binding assays, MARK2 kinase assay and S223 phospho-site mutagenesis with dimerization/binding readouts, and UBAC2 loss-of-function mouse colitis models with UPR and inflammation measurements

   PMID:39284914 PMID:39580148

   Open questions at the time

   • Structural basis of S223-driven dimerization not solved
   • How dimerization mechanistically enhances GABARAP avidity not detailed
   • Relationship between ER-phagy receptor role and the earlier ubiquitin-binding/NF-κB functions not reconciled

• How the ubiquitin-binding domain of UBAC2 and its proteasomal turnover integrate with its ER-phagy receptor function and NF-κB suppression remains unresolved.
• No identified E3 ligase or ubiquitin ligand for the ubiquitin-binding domain
• Unclear whether ER-phagy and NF-κB regulation are the same or parallel pathways
• No structural model of the full receptor